7th ICHNO Abstract book

7th ICHNO 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ page 35

In our experience, IMRT delivered with concurrent Cet is a well-tolerated option for patients with locally advanced HNSCC unfit for DDP with good oncologic and toxicity profiles. Patients comorbidities burden do not affect OS. Low rates of discontinued treatment have been reported. PO-066 Primary laryngectomy vs chemoradiotherapy in T3 laryngeal cancer: a comparison of treatment outcomes A. Owen 1 , L. Pope 1 1 Morriston Hospital, Otolaryngology, Swansea, United Kingdom Purpose or Objective The aim of the study was to identify if there was a significant survival or functional advantage to primary laryngectomy or chemoradiotherapy in the treatment of Data was collected using the Cancer Network Information System Cymru (CaNISC) database for all diagnoses of T3 laryngeal cancer in the last 10 years (December 2007 – December 2017) across 5 hospital sites in the South/West Wales region. A Kaplan-Meir survival curve was compiled using the raw data to demonstrate 10 year survival statistics for each treatment arm. Statistical significance of the mortality of salvage laryngectomy patients was analysed using a Chi Squared test. All data was analysed using SPSS statistical software. Speech and language therapy files obtained for each individual case attempted to assess functional outcome based on quality of swallow and necessity for PEG feed post treatment. Results N=74 confirmed diagnosis T3 laryngeal carcinoma across all 5 sites in the last 10 years. Out of these 74, 43 received chemoradiotherapy and 29 received primary laryngectomy. 14% (6) of the primary chemo/radiotherapy group converted to salvage laryngectomy. Out of those 6, 2 died ( p= 0.85 ) . 10 year survival of chemo/radiotherapy and primary laryngectomy was 70% and 69% respectively ( p= 0.987). Conclusion No significant survival advantage to either treatment arm was demonstrated. Salvage laryngectomy did not significantly increase mortality of patients. Further study is still ongoing with regards to functional outcome. For now, clinicians should continue to treat T3 laryngeal cancer on presentation of function. PO-067 Should we consider the hippocampus when optimizing the IMRT of NPC? W. Mnejja 1 , H. Daoud 1 , L. Farhat 1 , N. Fourati 1 , W. Siala 1 , J. Daoud 1 1 Hbib Bourguiba Hospital, radiotherapy, sfax, Tunisia Purpose or Objective Intensity-modulated radiation therapy (IMRT) of nasopharyngeal carcinomas (NPCs) aimed to preserve quality of life by limiting the dose to at risk organs. The hippocampus is involved in learning and long-term memory. A dose greater than 7.3 Gy in 40% of its volume would be associated with a deterioration of cognitive functions. We proposed in this work to evaluate the dose received by this organ during the IMRT for NPC. Material and Methods Twenty patients treated with IMRT for NPC were enrolled in this retrospective dosimetric study. In the initial planning, we did not consider the hippocampus as an organ at risk. His contouring was done secondarily. We recorded the D40% received by the hippocampus. The correlation of T3 laryngeal cancer. Material and Methods

patients affected with locally advanced oropharynx and hypopharynx/larynx cancer treated with concurrent Cet and IMRT at the Centro di Riferimento Oncologico in Aviano. Material and Methods We reviewed all unfit patients treated at our Institution with radical IMRT and concomitant Cet. Inclusion criteria included: 1) histologic proof of squamous cell carcinoma from the head and neck district, 2) multidisciplinary assessment and contraindication to surgery or DDP based regimen, 3) no evidence of distant metastases. All patients gave written informed consent for treatment and data collection for scientific purposes. All patients data were analyzed with descriptive statistics. Outcomes analysis was elaborated with Kaplan-Meier curves.

Results Twenty-six patients met strictly the inclusion criteria. Baseline characteristics are shown in table 1. Median follow up was 12.1 months (range 9.2-60.1 months). Median dose of IMRT delivered was 70.95Gy in 33 fractions (2.15Gy/fr). Median overall duration of IMRT was 48.5 days (range: 39-122 days). Median number of cycles of Cet administered per patients was 6 (range: 2-8 cycles). Treatment discontinuation was observed in 4 patients (15%) with median overall treatment duration of 86 days (range: 62-122 days). Two years - Relapse Free Survival, Head and Neck cancer Specific Survival (HNSS) and Overall Survival (OS) were 56%, 77% and 81%, respectively. The burden of comorbidities expressed as Charlson Comorbidity Index (CCI) showed no differences in OS in patients with low or high score (figure 1). Acute Toxicity G3 was observed 19 out of 26 patients. No late toxicity of G3 or more was observed.

Conclusion